ARQT

Arcutis Biotherapeutics Inc.

Price

$26.46

return (12m)

67.79%

p/e

118.59

p/bv

15.33

DIVIDEND YIELD

0.00%

ARQT price

Arcutis Biotherapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment ARQT

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-5.36%

3 months

25.94%

1 year

67.79%

2 years

205.90%

5 years

30.67%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals ARQT

Valuation

P/E

118.59

Sector -4.38

Industry -4.38

P/BV

15.33

Sector 2.02

Industry 2.02

P/Revenue (PSR)

7.29

Sector -4.40

Industry -4.40

EV/EBITDA

169.78

Sector -263.09

Industry -263.09

EV/EBIT

174.91

Sector -702.90

Industry -702.90

P/EBITDA

74.49

Sector -4.39

Industry -4.39

P/EBIT

78.36

Sector -4.73

Industry -4.73

P/Total Assets

6.92

Sector 1.49

Industry 1.49

P/Net Current Assets

16.93

Sector -11.70

Industry -11.70

P/Working Capital

11.00

Sector -3.19

Industry -3.19

EPS

0.22

Sector -2.14

Industry -2.14

BVPS

1.68

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

91.14%

Sector 36.74%

Industry 36.74%

EBITDA Margin

14.72%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

14.28%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

7.38%

Sector -38.22%

Industry -38.22%

Net Profit Margins

6.14%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.27

Sector 0.03

Industry 0.03

Profitability

ROE

12.93%

Sector -65.14%

Industry -65.14%

ROA

5.84%

Sector -65.53%

Industry -65.53%

ROIC

64.11%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

2.92

Sector 2.90

Industry 2.90

Net Debt / EBITDA

-7.15

Sector -6.07

Industry -6.07

Net Debt / EBIT

-7.36

Sector -8.26

Industry -8.26

Net Debt / Equity

-0.62

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.46

Sector -0.05

Industry -0.05

Equity/Assets

0.45

Sector 0.41

Industry 0.41

Liabilities/Assets

0.55

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

FAIR VALUE OF Arcutis Biotherapeutics ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$26.46

Fair Value

$2.88

Upside Return potential.

-89.10%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals ARQT

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
ARQT Arcutis Biotherapeutics Inc.	$26.46	58.06%	0.00%	118.59	15.33	12.93%	6.14%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

ARQT Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Arcutis Biotherapeutics

Arcutis Biotherapeutics Inc.

Average Investor10 user rating

4.0 (4 people)

United States

10 years

Founded: 2016

2020

Time since IPO - 6 years

29

Employees

Arcutis Biotherapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $3.38 billion, with shareholders equity totaling $220.58 million.

The company employs approximately 29 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Arcutis Biotherapeutics Inc. reported $463.98 million in revenue, generating net income of $28.51 million.

Key financial metrics include a P/E ratio of 118.59, a price-to-book (P/B) ratio of 15.33, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker ARQT.

Market cap

$3.38 billion

Net worth

$220.58 million

$220,580,000.00

Assets

$488.54 million

$488,540,000.00

Total Shares Outstanding

131.00 million

131,000,000

Average Daily Trading Volume

$1.65 million

$1,651,864.92

Sector

Health Care

Industry

Biotechnology

ARQT

ARQT revenue and profits

Financial Results ARQT

DRAG THE FRAME TO SEE MORE DATA

ARQT cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Arcutis Biotherapeutics (ARQT) today?

A cotação de Arcutis Biotherapeutics (ARQT) hoje está em US$ 26.46, com uma variação de 67.79% em relação ao último ano. A cotação de Arcutis Biotherapeutics (ARQT) iniciou o ano negociando na casa dos US$ 29.04 e hoje está em US$ 26.46. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Arcutis Biotherapeutics (ARQT) e dados de ações do Ibovespa e mercados internacionais.

Quando Arcutis Biotherapeutics (ARQT) paga dividendos?

Arcutis Biotherapeutics (ARQT) não distribuiu dividendos no último ano.

Is Arcutis Biotherapeutics (ARQT) a good investment?

Atualmente, Arcutis Biotherapeutics (ARQT) está cotada a US$ 26.46, com um P/L de 118.59, representando um desvio de -2,329% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 67.79 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 67.79%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Arcutis Biotherapeutics (ARQT) stock?

Investir em ações de Arcutis Biotherapeutics (ARQT) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Arcutis Biotherapeutics (ARQT) yield today?

A rentabilidade de Arcutis Biotherapeutics (ARQT) foi de -5.36% no último mês, 67.79% no último ano e 30.67% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Arcutis Biotherapeutics (ARQT) hoje, o investimento total seria de US$ 2,646.00, com base na cotação atual de US$ 26.46.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 4,439.72
Em 5 anos: US$ 3,457.53
Em 10 anos: US$ 2,646.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

ARQT

Arcutis Biotherapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment ARQT

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING ARQT WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Arcutis Biotherapeutics

Arcutis Biotherapeutics Inc.

United States

10 years

2020

29

PROFIT X PRICE ARQT

Financial Results ARQT

ARQT cash flow

Asset, Revenue and Profit Growth - ARQT

ARQT balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions